43 completed, 8 active not recruiting, 7 terminated, 6 recruiting. 39 Phase 2, 19 Phase 3, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 39 | Completed 21, Active not recruiting 6, Not yet recruiting 3, Recruiting 3, Terminated 3, Unknown 3 |
| Phase 3 | 19 | Completed 15, Terminated 4 |
| Phase 1 | 4 | Completed 3, Terminated 1 |
Follow French Innovative Leukemia Organisation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL). Pirtobrutinib, Fludarabine, Cyclophosphamide - CLL (Chronic Lymphocytic Leukemia) | Phase 2 | Not yet recruiting | French Innovative Leukemia Organisation | 82 | 2026-09-01 | 2026-06-03 |
| Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy. Ivosidenib + oral azacitidine - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | French Innovative Leukemia Organisation | 60 | 2026-09-01 | 2026-03-11 |
| Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients Venetoclax, Tagraxofusp - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 2 | Recruiting | French Innovative Leukemia Organisation | 33 | 2025-12-11 | 2026-07-01 |
| Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström Macroglobulinemia zanubrutinib + BGB-11417 - Waldenstrom Macroglobulinemia | Phase 2 | Not yet recruiting | French Innovative Leukemia Organisation | 102 | 2025-12-01 | 2025-11-26 |
| OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia AML, Adult | Recruiting | French Innovative Leukemia Organisation | 250 | 2024-07-31 | 2025-11-26 | |
| Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine AML, Adult | Unknown | French Innovative Leukemia Organisation | 230 | 2024-07-04 | 2024-07-23 | |
| Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome Glofitamab + Obinutuzumab - Richter Syndrome | Phase 2 | Recruiting | French Innovative Leukemia Organisation | 40 | 2024-03-21 | 2026-06-30 |
| Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia AzaCITIDine Oral Tablet, Xospata - AML, Adult, Refractory AML | Phase 2 | Recruiting | French Innovative Leukemia Organisation | 33 | 2024-01-13 | 2025-03-24 |
| Prognostic Analyses on a Validation Series of Patients With Waldenström's Disease Waldenstrom's Disease, Prognostic Index | Recruiting | French Innovative Leukemia Organisation | 500 | 2023-08-11 | 2025-11-26 | |
| REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy CLL, Relapsed, CLL, Refractory | Completed | French Innovative Leukemia Organisation | 152 | 2023-01-25 | 2025-12-03 | |
| French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Settings First line therapy - CLL/SLL | Active not recruiting | French Innovative Leukemia Organisation | 1000 | 2022-11-11 | 2025-12-03 | |
| Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission Cytarabine-Venetoclax Association, Cytarabine-Idarubicin Association - Acute Myeloid Leukemia | Phase 2 | Active not recruiting | French Innovative Leukemia Organisation | 134 | 2022-05-25 | 2024-06-27 |
| Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm CPX-351 - Acute Myeloid Leukemia, Myeloproliferative Syndrome | Phase 2 | Completed | French Innovative Leukemia Organisation | 42 | 2022-03-23 | 2024-10-29 |
| STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia Stop ACA, ACA Continuation - Untreated Chronic Lymphocytic Leukemia | Phase 2 | Active not recruiting | French Innovative Leukemia Organisation | 160 | 2021-10-18 | 2025-12-03 |
| A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE Refractory AML, Relapsed Adult AML | Completed | French Innovative Leukemia Organisation | 177 | 2021-07-05 | 2023-05-24 | |
| Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19 Acute Myeloblastic Leukemia, Acute Lymphoblastic Leukemia | Completed | French Innovative Leukemia Organisation | 79 | 2020-09-11 | 2022-07-27 | |
| Observatory of Prolymphocytic Leukemia T Molecular caracterization - Prolymphocytic Leukemia, T-cell Leukemia | Active not recruiting | French Innovative Leukemia Organisation | 50 | 2020-07-01 | 2026-10-19 | |
| COVID-19 Epidemic and Patients With Myeloproliferative Neoplasias Myeloproliferative Neoplasm, COVID-19 Infection | Completed | French Innovative Leukemia Organisation | 1793 | 2020-05-18 | 2022-10-18 | |
| Observatory of Patients With Chronic Lymphocytic Leukemia / Lymphocytic Lymphoma or Waldenstrom Disease Infected With COVID-19 Data registry - Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma or Waldenstrom Disease | Completed | French Innovative Leukemia Organisation | 162 | 2020-03-14 | 2023-05-24 | |
| Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia venetoclax and ibrutinib (I+VEN), FCR - Intermediate Risk Chronic Lymphocytic Leukemia, Fit Patients | Phase 2 | Completed | French Innovative Leukemia Organisation | 120 | 2019-09-27 | 2025-11-26 |
Showing 20 of 72. Sign in to see all of them.
Leukemia, Myeloid, Acute (20) · Leukemia, Lymphocytic, Chronic, B-Cell (8) · Lymphoma (7) · Lymphoma, Mantle-Cell (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Lymphoma, B-Cell (3) · Lymphoma, Follicular (3) · Recurrence (3) · Waldenstrom Macroglobulinemia (3) · Leukemia (2) · Leukemia, B-Cell (2) · Primary Myelofibrosis (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · COVID-19 (1) · Hodgkin Disease (1)
Rituximab (11) · Cyclophosphamide (6) · Doxorubicin (6) · fludarabine (6) · Dexamethasone (4) · Vincristine (4) · obinutuzumab (4) · Azacitidine (3) · Prednisone (3) · ibrutinib (3) · venetoclax (3) · Bendamustine Hydrochloride (2) · Chlorambucil (2) · Cytarabine (2) · Drug Therapy (2)
France (68) · Australia (1) · Austria (1) · Belgium (1) · Germany (1) · Netherlands (1) · Switzerland (1)
Jean-Francois Rossi, MD, PhD (2) · Arnaud Pigneux, Prof (1) · Caroline Dartigeas, MD (1)
PMID 15256423, PMID 16939487, PMID 17134114, PMID 18955565, PMID 20220059, PMID 20971822, PMID 21109011, PMID 22337714, PMID 23065509, PMID 23109692, PMID 23233721, PMID 23321257, PMID 23321953, PMID 24616160, PMID 26635039, PMID 26688235, PMID 27783363, PMID 27964867, PMID 28126961, PMID 28129526, PMID 28251914, PMID 28953447, PMID 29061568, PMID 29275118, PMID 29505137, PMID 29567785, PMID 30142422, PMID 31324600, PMID 33167024, PMID 33961019, PMID 35697729, PMID 36325355, PMID 37026799, PMID 38669626, PMID 39499299
2025 (1)